Corline Biomedical Ab · OMXSTO:CLBIO
Corline Biomedical Ab — Pareto Healthcare Conference 2021
22 slides from Corline Biomedical Ab's conference presentation, September 2021
Slide 1: Solutions for life
September 2021 Solutions for life 1
Slide 2: Advancing regenerative medicine through CHC™ coating technology
Advancing regenerative medicine through CHC™ coating technology • Proprietary heparin conjugate technology that reduces bleeding risks associated with Proprietary CHCTM systemic administration of heparin technology • Reduces coagulation, complement cascade activation and inflammation • Used for surf
Slide 3: CHC™ – proprietary heparin conjugate technology
CHC™ – proprietary heparin conjugate technology • Corline Heparin Conjugate (CHCTM) is a proteoglycan-like conjugate of covalently bound heparin • Heparin is a naturally occurring biomolecule routinely used in surgery as a systemic anticoagulant • CHC™ is used to locally increase concentration of he
Slide 4: Renaparin® – Improving the outcome of kidney transplantation
Renaparin® > Improving the outcome of kidney transplantation CHS™ Medical Devices Opportunities & validation 4
Slide 5: Ischemia/reperfusion injury – no drug approved for prevention
Ischemia/reperfusion injury – no drug approved for prevention Explantation Preservation Transplantation Ischemia Reperfusion injury Lack of natural blood flow and Immune thrombotic reaction when kidney is consequently insufficient oxygen supply connected to the recipient’s blood flow, causing damage
Slide 6: Organ shortage – a multi-faceted challenge for kidney transplantation
Organ shortage – a multi-faceted challenge for kidney transplantation Significant organ shortage gap remains… …driving acceptance of marginal donors US & EU5 Kidney transplants1 (2017) Deceased donor kidney transplants CAGR 2012-172 4.9% 3.1% US EU5 Increase in high KDPI and ECD donors3 KDPI 0-20 KD
Slide 7: Renaparin® – reducing risk of marginal donor kidney transplantation
Renaparin® – reducing risk of marginal donor kidney transplantation Explantation Renaparin® + Preservation Transplantation Ex vivo Standard Renaparin® + preservation treatment Renaparin® helps avoid delayed graft function -> reduced need for dialysis, duration of hospital stay and improved kidney fu
Slide 8: Promising results from proof-of-concept studies in small and large animals
Promising results from proof-of-concept studies in small and large animals Rapid effect of treatment1 Remaining functional benefit2 250 Baseline Day 4 Day 7 5 P=0.026 S-Creatinine (µmol/L) 200 Small animals 4 S-Creatinine (mg/dL) P=0.035 150 3 = control group 100 2 = Renaparin® 50 1 0 0 Transplantat
Slide 9: Clinical safety and tolerability demonstrated in recent Phase I study
Clinical safety and tolerability demonstrated in recent Phase I study • Phase I interventional, double-blind, randomized, controlled study of kidney transplantation after ex vivo treatment with Description Renaparin® of kidneys from deceased donors • Multi-center in Sweden, at 3 sites: Uppsala, Stoc
Slide 10: Phase II study design
Phase II study design • Phase II interventional, single-blind, randomized, controlled study of kidney transplantation after ex vivo treatment with Description Renaparin® of kidneys from deceased donors • Multi-center in EU, at 4-10 sites in 2 countries • Primary objective: assess efficacy of donor k
Slide 11: Peak Sales Estimates – US focus for pivotal study
Peak Sales Estimates – US focus for pivotal study PEAK SALES ESTIMATE* US USD 7,800 x 16,500 treated kidneys ≈ USD 130 million Renaparin® EU USD 3,000 x 20,000 treated kidneys ≈ USD 60 million 11 Source: (*) GroupH market access study; assumption is high penetration in high risk cases and low to no
Slide 12: CHS™ Medical Devices – Anti-thrombotic coating for vascular devices
Renaparin® > Improving the outcome of kidney transplantation CHS™ Medical Devices > Anti-thrombotic coating for vascular devices Opportunities & validation 12
Slide 13: CHS™ for medical devices – prospects of near-term revenues and high margins
CHS™ for medical devices – prospects of near-term revenues and high margins Thrombosis in medical device use Coating with CHS™ → Corline Heparin Surface (CHS™) coating system can be used on any → Artificial surfaces can cause thrombotic type of medical device material reactions upon contact with blo
Slide 14: Establishing a track-record within device coating
Establishing a track-record within device coating Current status Future potential >100,000 Global medical device coatings patients in EU have received coronary market1 (USDm) stents coated with CHS™ 566 SEK 35m 372 expected annual income on full roll-out of CHS™ treated stroke care product – more in
Slide 15: CHS™ equals best-in-class performance
CHS™ equals best-in-class performance Primate model platelet adherence Visual inspection 15
Slide 16: CHS™ business models
CHS™ business models Coating Service model Out-licensing model ✓ CHS™ is applied to device in Corline ✓ CHS™ is applied by customer at Biomedical’s clean room facility in customer site or 3rd party Uppsala, Sweden ✓ Customer invests in developing and ✓ Corline invests in developing and maintaining c
Slide 17: CHS™ customer case
CHS™ customer case Founded in 2007 and headquartered in Vancouver, Canada, Kardium sells atrium fibrillation devices to treat heart arrythmia. More than 200 employees in Canada and in Dortmund, Germany, goal of 400 employees within 18 months. CHS™ is used on the Globe Mapping System, which is an adv
Slide 18: as bench mark
as bench mark Approved products Revenue and EBIT (000’ SEK) Berlin Heart EXCOR® Ventricular Assist Device 2018 2019 2020 Revenue 183 520 226 774 215 004 EBIT 114 239 197 966 140 615 GORE® PROPATEN® Vascular Graft GORE® PROPATEN® configured for Pediatric Shunt CBAS® vs CHS™ GORE® VIABAHN® Endoprosthe
Slide 19: H1 2021 financial report
H1 2021 financial report 2021 H1 report • Net revenue 2 860 KSEK (792) strengthens view of • Net results -3 558 KSEK (-5 082) Corline Biomedical • Net result/share -0.18 SEK (-0.30) as a company with two attractive • Cash, June 30: 47.7 MSEK (12.4) business segments
Slide 20: Leadership team
Leadership team Management Board Henrik Nittmar, PhD Gunnar Tufveson, Prof, MD Adam Dahlberg CEO Chief Medical Officer Chairman Åsa Holm, PhD Fredrik Carlsson, PhD Lars Sunnanväder Regulatory & Quality Assurance Manager Research Manager Board Member Patrizia Caldirola, PhD Gunilla Ekström Project Ma
Slide 21: Advancing regenerative medicine through CHC™ coating technology
Advancing regenerative medicine through CHC™ coating technology • Proprietary heparin conjugate technology that reduces bleeding risks associated with Proprietary CHCTM systemic administration of heparin technology • Reduces coagulation, complement cascade activation and inflammation • Used for surf
Slide 22: NASDAQ FN:CLBIO
— liomedical NASDAQ FN:CLBIO
Corline Biomedical — Pareto Healthcare Conference 2021 on 6ix